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Patients with chronic kidney disease (CKD) requiring dialysis have a higher risk of 
infection and sepsis (1) due to uremia-induced immune deficiency, significant co-
morbidities and the dialysis procedure itself. Dialysis patients with sepsis have a 100-
fold higher mortality than other patients with sepsis (2). The severity of myocardial 
dysfunction is an important predictor of morbidity and mortality among patients with 
sepsis (3). However, it is unknown whether pre-existing CKD worsens the cardiac 
outcome in animals or man with sepsis. This study was designed to investigate the 
effects of lipopolysaccharide (LPS) administration or cecum ligation and puncture 
(CLP) on cardiac performance in mice with CKD. 
Male C57BL/6 mice (age: 4-6 weeks) were subjected to a two-stage, subtotal (5/6th) 
nephrectomy (SNX). After 8 weeks, mice with SNX/CKD were subjected to either 
low dose LPS (2mg/kg i.p.) administration or CLP. At 18 hours after LPS injection or 
24 hours after CLP, cardiac function was evaluated by echocardiography. The 
following signal transduction events were evaluated in the heart of all animals by 
Western blot analysis:  (a) Phosphorylation of the inhibitor of κBα (IκBα), (b) the 
nuclear translocation of the nuclear factor κB (NF-κB) subunit p65, (c) expression of 
iNOS, (d) phosphorylation of Akt and (e) phosphorylation of ERK1/2. All data is 
represented as mean ± standard error of the mean (SEM). Data was analyzed either by 
using unpaired Student’s t-test (for comparisons between two groups) or by one-way 
ANOVA followed by Bonferroni’s post hoc test for multiple comparisons. A p-value 
of p<0.05 was considered significant. 
When compared to age-matched sham mice, SNX for 8 weeks resulted in a significant 
rise in urea (from 8.17 ± 0.41, n=12; to 17.43 ± 0.61 mmol/L, n=14; p<0.05) and 
creatinine (from 29.72 ± 0.38, n=12; to 45.96 ± 1.76 µmol/L, n=14; p<0.05), 
indicating development of CKD. Moreover, when compared to sham mice, mice with 
CKD showed a slight, but significant, decrease in ejection fraction (EF) (from 72.78 ± 
0.56, n=11; to 65.25 ± 0.89%, n=23; p<0.05). In sham mice without CKD, the 
intraperitoneal administration of low dose LPS (2 mg/kg) for 18 hours or CLP for 24 
hours had no effect on EF (70.69 ± 1.24 and 72.26 ± 0.89%, respectively, n=6-7; 
p>0.05). In contrast, administration of low dose LPS (2 mg/kg) or CLP in mice with 
CKD caused profound reductions in EF (to 40.38 ± 2.77 and 41.74 ± 1.31%, 
respectively, n=7 per group; both p<0.05). Interestingly, compared with sham mice, 
western blot analysis of the myocardium from mice with CKD revealed profound 
increases in phosphorylation of IκBα, nuclear translocation of the NF-κB subunit p65, 
increased expression of iNOS protein, and significant increases in phosphorylation of 
Akt and ERK1/2. Moreover in mice with CKD, administration of low dose LPS or 
CLP further increased the phosphorylation of IκBα, the nuclear translocation of the 
NF-κB subunit p65 and the expression of iNOS. In contrast, administration of LPS or 
CLP to mice, which did not have CKD, had no significant effect on any of the above 
signalling pathways. 
In conclusion, the presence of CKD aggravates the cardiac dysfunction caused by LPS 
or CLP in the mouse. The observed increase in the severity of cardiac dysfunction in 
CKD mice with sepsis was associated with and may (at least in part) be due to 
increased cardiac activation of NF-κB and increased expression of iNOS, both of 
which are known to contribute to the cardiac dysfunction caused by sepsis (4, 5). 
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